Steward Partners Investment Advisory LLC grew its position in shares of UiPath Inc. (NYSE:PATH – Free Report) by 99.8% during ...

Q4 2025 Earnings Call Transcript March 12, 2025 UiPath Inc. beats earnings expectations. Reported EPS is $0.26, expectations ...

Stock analysts at DA Davidson upped their FY2026 earnings per share (EPS) estimates for UiPath in a research report issued on Thursday, March 13th. DA Davidson analyst G. Luria now expects that the ...

UiPath Inc (NYSE: PATH) stock declined on weak Q4 revenue and Q1 guidance. Needham analyst reiterated Hold. Deal delays and ...

UiPath Inc (PATH) reports robust Q4 2025 results with a 14% increase in ARR, despite facing geopolitical and economic headwinds.

UiPath's Q4 results show margin improvements, but analyst cautions on AI transition and growth pressure, lowering price ...

UiPath's growth slows to a crawl as it chases agentic AI dream with Peak acquisition, and its stock falls sharply - SiliconANGLE ...

Learn more about whether Manhattan Associates, Inc. or UiPath Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

UiPath (PATH) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

In the biotech sphere, ARK ETFs continued to accumulate shares of CRISPR Therapeutics AG (NASDAQ: CRSP) and Intellia Therapeutics Inc (NASDAQ: NTLA ), with purchases of 67,787 and 194,844 shares, ...